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Abstract
Pancreatic cancer remains a challenging disease with an overall cumulative 5-year survival rate
below 1%. The process of cancer initiation, progression and metastasis is still not understood well.
Invasion and tumor metastasis are closely related and both occur within a tumour-host
microecology, where stroma and tumour cells exchange enzymes and cytokines that modify the
local extracellular matrix, stimulate cell migration, and promote cell proliferation and tumor cell
survival. During the last decade considerable progress has been made in understanding genetic
alterations of genes involved in local and systemic tumor growth. The most important changes
occur in genes which regulate cell cycle progression, extracellular matrix homeostasis and cell
migration. Furthermore, there is growing evidence that epigenetic factors including angiogenesis
and lymphangiogenesis may participate in the formation of tumor metastasis. In this review we
highlight the most important genetic alterations involved in tumor invasion and metastasis and
further outline the role of tumor angiogenesis and lymphangiogenesis in systemic tumor
dissemination.
Review
Pancreatic cancer remains an unfortunate disease with a 5-
year survival rate below 1%. Thus it represents one of the
leading causes of cancer related death in industrialized
countries despite advances in medical therapy and surgi-
cal techniques [1]. One of the major hallmarks of pancre-
atic cancer is its early systemic dissemination and its
extraordinary local tumor progression [2]. These features
may contribute to more than 3/4 of patients diagnosed
with this disease can not be offered curative treatment
and, therefore, may determine the high mortality rate
among patients with pancreatic cancer [1].
One standing problem in the therapy of pancreatic cancer
is metastatic disease. How metastatic progression devel-
ops is unknown in as much as little is known on how ma-
lignant cells detach from the primary tumor site and grow
in distant organs [3]. Invasion and metastasis occur with-
in a tumour-host microecology, where stroma and tu-
mour cells exchange signals that modify the local
extracellular matrix, stimulate migration, and promote
proliferation and survival [4]. In general the genetic varia-
bility of cancer cells leads to the manifestation of six es-
sential alterations that collectively dictate malignant, and
most likely also metastatic and invasive tumor growth:
self-sufficiency in growth signals, insensitivity to growth-
inhibitory (antigrowth) signals, evasion of programmed
cell death (apoptosis), limitless replicative potential, sus-
tained angiogenesis, and tissue invasion and metastasis
[4].
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In the present review we will focus on the impact of mo-
lecular alterations including metalloproteinases, the plas-
minogen activator/plasmin system and tumor metastasis
suppressor genes and we will highlight the role of angio-
genesis and lymphangiogenesis in pancreatic cancer pro-
gression.
Genetic instability and tumor progression
The understanding of the molecular mechanisms of tu-
mor growth and metastasis is one of the most important
issues in cancer research. It is necessary to identify genetic
but also epigenetic determinants which govern systemic
tumor dissemination. Since cancer is attributed to genetic
alterations it is indispensable to identify those genes
whose alterations accumulate during tumor progression.
Over the past two decades, a number of these genes have
been identified. In 1980, identification of oncogenes
opened the way to specifically search for genetic altera-
tions in human cancers [5]. In the late 1980s and 1990s,
isolation of tumor suppressor genes further accelerated
the understanding of the genetic network. In the early pe-
riod restriction fragment length polymorphism analysis
(RFLP) of tumor suppressor genes [6] identified that loss
of heterozygosity (LOH) – a hallmark of gene inactivation
– occurs frequently at multiple chromosomal loci in a va-
riety of human cancers including pancreatic cancer [7]
The presence of multiple genetic alterations in human
cancers strongly indicated that alterations accumulate
during tumor progression. Comparative analysis of these
genetic alterations in early and late stage tumors led to the
hypothesis of a multistage carcinogenesis in colorectal
cancer progression which now is a widely accepted genetic
tumor progression model [8]. A similar progression mod-
el has recently been postulated for pancreatic cancer,
where an adenoma-carcinoma sequence is proposed [9].
Based on the concept of multistage carcinogenesis, the
metastatic activity of cancer cells should be defined by
those genes whose alterations accumulate predominantly
in late stage cancer cells.
What makes pancreatic cancer invasive and metastatic
Sooner or later during the development of pancreatic can-
cer the primary tumor mass spawns pioneer cells that
move out, invade adjacent tissues, and circulate to distant
organs where they may form new colonies. These process-
es are responsible for ~90% of pancreatic cancer deaths in
patients [2]. Once metastatic cells settled in distant organs
nutrients and space are no longer limited because newly
formed metastases arise as islets of cancer cells surround-
ed by normal cells of the host tissue. Invasion and metas-
tasis are complex processes, and their genetic and
biochemical determinants are still largely unknown.
Mechanistically they are closely related since both utilize
similar strategies, involving changes in the physical cou-
pling of cells to their microenvironment and activation of
extracellular proteases. It is known that the movement of
neoplastic cells is not a random process, even so the
mechanisms governing their movement, survival in for-
eign tissue environments, and choice of residence at a fi-
nal destination have remained uncertain [4].
Several controversial theories exist to explain the metastat-
ic specificity. Among them, the homing theory suggests
that organs distant to sites of primary malignancy actively
attract malignant cells via expression of adhesion recep-
tors or by secretion of soluble chemotactic factors [10].
Identification of molecular addresses or adhesion recep-
tors on endothelial cells in vascular beds of distal organs
that specifically trap circulating malignant cells supports
the active arrest view of the homing theory [11]. In con-
trast, the fertile soil theory proposes that different organ
environments provide variable growth conditions for spe-
cific circulating cell types. It seems likely that distinct
mechanisms/molecules might govern a malignant cell's
journey to an ectopic tissue, separate from those regulat-
ing its growth and/or survival once its destination has
been achieved [4]. Tumor invasion encompasses the proc-
ess of tumor cell penetration or infiltration into adjacent
tissue. This event is also central and related to the devel-
opment of metastasis. Loss of junctional contact between
adjacent epithelial cells and cell-extracellular matrix asso-
ciation are essential prerequisites for tumor cell detach-
ment from the primary tumor site [12]. It is postulated
that migration and invasion of cancer cells into surround-
ing stroma are prevented by cell-cell and cell-matrix adhe-
sion molecules. Disruption of these adhesive connections
leads to increased motility of tumor cells, which detach
from the primary lesion. Therefore, adhesion molecules
on the cell surface play an important role in tumor cell mi-
gration and regulate the potential for epithelial cells to
metastasize.
Cell adhesion molecules and their role in metastasis
Several classes of proteins are participating when cells ex-
hibit an invasive or metastatic phenotype. This includes
cell-cell adhesion molecules (CAMs) like members of the
immunoglobulin and calcium-dependent cadherin fami-
lies and integrins [13]. Notably, all of these "adherence"
interactions convey regulatory signals to the cell [14]. One
widely observed alteration in cell-to-environment interac-
tion in pancreatic cancer involves E-cadherin, which cou-
ples adjacent cells by E-cadherin bridges. As a result the
transmission of antigrowth signals is mediated via cyto-
plasmic contacts with catenin to intracellular signaling cir-
cuits that include the Lef/Tcf transcription factor [15]. E-
cadherin function is lost in a majority of pancreatic tu-
mors [16]. Currently, the presence of E-cadherin is consid-
ered as an important suppressor of invasion andMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/14
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metastasis and its functional elimination may represent a
key step in the acquisition of this phenotype.
Alterations of cell adhesion molecule expression in the
immunoglobulin superfamily also appear to play critical
role in invasion and metastasis [17,18]. Clearly N-CAM
undergoes a switch in expression from a highly adhesive
isoform to poorly adhesive forms and its down regulation
leads to invasive pancreatic cancer [19]. Furthermore, dif-
ferential expression of the cell adhesion molecules ICAM-
1 (intercellular adhesion molecule-1), VCAM-1 (vascular
cell adhesion molecule-1), and ELAM-1 (endothelial leu-
kocyte adhesion molecule-1) in human pancreatic cancer
has recently been studied [20]. Northern blot analysis re-
vealed a 5.4-fold increase of ICAM-1 and a 3.7-fold in-
crease in VCAM-1 mRNA expression in cancer samples in
comparison with normal controls. In contrast, ELAM-1
mRNA levels did not show significant differences between
cancer and normal tissues. Therefore, it is likely that en-
hanced ICAM-1 and VCAM-1 expression plays a role in
human pancreatic cancer pathogenesis, where they likely
contribute to cancer cell migration and the spread of can-
cer cells to distant organs, or both [20].
Changes in integrin expression are also evident in invasive
and metastatic pancreatic cancer cells. The importance of
integrins in tumor cell dissemination is their role in cellu-
lar adaptation to changing tissue microenvironments as
found in metastatic organs. This is achieved through vari-
ous permutations in the spectrum of the more than 22 in-
tegrin subtypes. Experimental changes in expression of
integrin subunits in cultured cells induces or inhibits in-
vasive and metastatic growth, which confers their role as
central determinants of these processes [21].
The second class of players in transforming pancreatic
cancer into an invasive and metastatic phenotype are ex-
tracellular proteases [22]. Several studies in pancreatic
cancer indicate that proteases are upregulated, protease
inhibitors are downregulated, and inactive zymogen
forms of proteases are converted into active enzymes [23].
One imagines that docking of active proteases on the cell
surface can facilitate invasion by cancer cells into nearby
stroma, across blood vessel walls, and through normal ep-
ithelial cell layers. However, this theory is getting even
more complex due to multiple cell types involved in pro-
tease expression and display. In many types of carcino-
mas, matrix-degrading proteases are produced by
conscripted stromal and inflammatory cells but not by the
epithelial cancer cells [24]. For example, in the case of
pancreatic cancer there is evidence that certain cancer cells
induce urokinase (uPA) expression in stromal cells, which
then bind to the urokinase receptor (uPAR) expressed on
the cancer cells [25].
The role of matrix metalloproteases in pancreatic cancer 
dissemination
Recent studies of the activity of matrix metalloproteases
(MMPs) and their tissue inhibitors (TIMPS) in invasive
neoplasms have indicated that these enzymes play an im-
portant role in the degradation of connective tissue which
is associated with the development of tumor metastases
[26]. The matrix metalloproteases comprise a family of se-
creted or transmembrane proteins. Currently at least 15
structurally related members with a broad spectrum of
proteolytic activities against components of the extracellu-
lar matrix have been identified. Based on their substrate
specificities, MMPs have been categorized into five
groups: collagenases, gelatinases, stromelysins, metalloe-
lastases and the newly identified membrane-type MMP. In
particular, MMP-2 and MMP-9 (gelatinase A and gelati-
nase B) are involved in the systemic dissemination of tu-
mors. The importance of MMPs during tumor metastasis
may be related to their proteolytic activity against type IV
collagen, which is a major component of epithelial base-
ment membranes [26]. The proteolytic acitivity of MMPs
is regulated at different levels, including regulation of
mRNA transcription by biologically active agents such as
growth factors, hormones and oncogens, as well as regu-
lation at the level of mRNA stability and translation. Most
of the MMPs are produced in the form of biologically in-
active proenzymes and need to become activated. For ex-
ample, activation of MMP-2 involves the action of a
membrane-type 1 matrix metalloproteinase (MT-1-MMP)
which cleaves a portion of the carboxy terminus of pro-
MMP-2 [27]. Once MMP-2 is active, it is susceptible for in-
hibition by a family of so called specific tissue inhibitors
of metalloproteinases (TIMPS). Nowadays, there is strong
experimental evidence that MMPs play a major role in lo-
cal and systemic growth of pancreatic cancer [28]. Further-
more, high expression of MT1-MMP and MT2-MMP,
MMP-2, and MMP-9, as well as TIMP-1 and TIMP-2 was
found in pancreatic cancer [29]. Recent studies suggested
that members of the MMPs also enhance tumor angiogen-
esis by triggering the angiogenic switch [24].
The plasminogen activator /plasmin system
In addition to the MMP family, the plasminogen activa-
tor/plasmin system has been implicated in tumor inva-
sion and metastasis. Plasmin participates in tissue
degradation and is activated from the inactive precursor
plasminogen by two types of plasminogen activators –
uPA (urokinase plasminogen activator) and tPA (tissue
plasminogen activator) [30]. The proteolytic activity of
uPA plays a dominant role in cell migration, angiogenesis,
and tumor metastases and is tightly regulated by proteo-
lytic cleavage. It is released from various cell types as an in-
active proenzyme (pro-uPA) which upon cleavage by
proteinases becomes enzymatically active [31]. uPA binds
to a specific cell surface receptor the Urokinase Plasmino-Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/14
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gen Activator Receptor (uPAR). Upon binding, uPA con-
verts the zymogen plasminogen to plasmin, an enzyme
which degrades fibrin and numerous other components
of the extracellular matrix, such as type IV collagen, fi-
bronectin and laminin [32]. This likely enables tumor
cells to migrate through tissue barriers [32,33]. Several
studies provided evidence that the expression of active
uPA by malignant cells correlates with their invasive po-
tential [34]. Elevated levels of uPA/uPAR have been re-
ported in numerous tumors, including pancreatic cancer
[25]. In patients with pancreatic cancer concomitant over-
expression of uPA and uPAR was found to be associated
with a shorter post-operative survival compared with
those patients in whom only uPA or its receptor were
overexpressed [25]. In a recent study, the u-PA/u-PA re-
ceptor proteolytic system has been reported to be in-
volved in the hepatocyte growth factor (HGF)-stimulated
motility of pancreas cancer cells [35]. HGF-induced cell
motility is significantly reduced by inhibitors of u-PA pro-
teolytic activity, such as antibodies neutralizing u-PA ac-
tivity, plasminogen activator inhibitor 1 and amiloride
[35]. Additionally, anti-uPA antibodies injected into mice
together with tumor cells caused a significant inhibition
of metastasis formation, providing strong evidence for the
involvement of this enzymatic system in tumor invasion
and metastases.
The KAI1 gene – A potential suppressor gene of metastasis 
lost in pancreatic cancer
Despite the number of genes which putatively regulate tu-
mor metastasis remains low, differential analysis identi-
fied some genes which may be involved in tumor
metastasis. Among the genes are p9Ka/mtal, KAI1, KiSS-1,
Tiam-1 and nm23-H1 [36,37]. Among the most interest-
ing genes involved in metastatic disease progression in
pancreatic cancer is the putative metastasis suppressor
gene, called KAI1, which was originally identified as me-
tastasis suppressor gene for prostate cancer [38]. The KAI1
protein is a member of the transmembrane-4 superfamily
(TM4SF) [39]. Additional studies revealed that decreased
KAI1 expression could be a useful marker for metastatic/
invasive potential in a series of human tumor types, in-
cluding cancers of the bladder, colon, breast and skin [40–
43]. In the case of pancreatic cancer KAI1 appears to be
crucial for the development of distant organ metastasis
since loss of KAI1 expression was found in lymph node
and distant metastasis [43,44]. For example, Northern
blot analysis showed increased steady-state levels of KAI1
mRNA in 89% of pancreatic cancer samples. These find-
ings were confirmed by in situ hybridization, by which en-
hanced KAI1 mRNA levels could be localized in
pancreatic cancer cells. In contrast, the stroma surround-
ing the cancer mass and normal pancreatic tissue adjacent
to the cancer cells exhibited very low levels of KAI1 mR-
NA. Correlation of mRNA levels obtained by Northern
blot analysis with clinical parameters of the patients re-
vealed that KAI1 mRNA levels were significantly higher in
earlier tumor stages than in advanced tumor stages, in
which lymph node or distant metastases were present.
These studies indicated that KAI1 mRNA expression is re-
duced in patients with advanced tumor stages and addi-
tionally revealed that pancreatic cancer cells of distant
metastases were devoid of KAI1 mRNA in comparison
with those of primary pancreatic cancers [44]. In addition,
KAI1 mRNA expression was shown to be associated with
poor prognosis in patients with pancreatic cancers but
also in patients with lung and breast cancers [44]. Those
studies suggest that down-regulation of KAI1 expression
may be an important step in metastatic progression of
many types of human cancers.
The role of Angiogenesis in local and systemic tumor 
growth
Oxygen and nutrients supplied by the vasculature are cru-
cial for cell function and survival. Thus, the formation of
new blood vessels (angiogenesis) is permissive for local
and systemic expansion of the tumor mass and can be in-
duced by multiple molecules that are released by both
cancer cells and stromal cells [45]. Angiogenesis itself en-
compasses a cascade of sequential processes emanating
from microvascular endothelial cells, which are stimulat-
ed to proliferate and degrade the endothelial basement
membrane of parental vessels, migrate, and penetrate into
host stroma and initiate a capillary sprout [46]. The re-
cruitment of endothelial cells during angiogenesis and the
formation of vascular tumors depends on the breakdown
of basement membranes, which occurs under control of
numerous activating factors that were shown to be overex-
pressed in pancreatic cancer, including vascular endothe-
lial growth factor (VEGF), bFGF, angiogenin, members of
the TGF and FGF gene families, and interleukin-8 (IL-8)
[47]. For instance, some of the pro-angiogenic cytokines
are overexpressed in pancreatic cancer tissues, and even
correlate with cancer aggressiveness and the patient's
prognosis [48]. In addition to neovascularization and dis-
ruption of cell-cell and cell-matrix adhesion, active prote-
olytic degradation of the extracellular matrix is required
when detached malignant cells start migrating through
the stroma surrounding the tumor [3]. A similar process
may be necessary when cells exit blood vessels to colonize
distant metastatic sites [3].
In order to progress to a larger size, incipient neoplasias
must develop an angiogenic ability [49]. The angiogen-
esis-initiating signals are exemplified by vascular endothe-
lial growth factor (VEGF) and acidic and basic fibroblast
growth factors (FGF1, FGF2). Each binds to transmem-
brane tyrosine kinase receptors displayed by endothelial
cells and in the case of pancreatic cancer even on cancerMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/14
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cells themselves thus creating autocrine growth stimula-
tion [50].
Integrin signaling also contributes to tumor neoangiogen-
esis. Quiescent vessels express one class of integrins,
whereas sprouting capillaries express another. Interfer-
ence with signaling from the latter class of integrins can
inhibit angiogenesis underscoring the important contri-
bution of cell adhesion to the angiogenic program which
has also been shown for pancreatic cancer [21]. Further-
more, extracellular proteases are physically and function-
ally connected with proangiogenic integrins, and both
help to dictate the invasive capability of angiogenic en-
dothelial cells [51].
Experimental evidence for the importance of inducing
and sustaining angiogenesis in tumors has been studied
extensively during the last couple of years [52]. Molecular
proof of principle came, for example, when VEGF as well
the VEGF receptors were therapeutically targeted and
proved able to impair neovascularization and growth of
tumors in mice [53,54].
Lymph-angiogenesis and lymphangio-invasion and its role 
in metastasis of pancreatic cancer
Tumor cells spread via the lymphatic system to regional
lymph nodes and finally into larger lymphatic vessels
which re-enter into the blood vascular system. In view of
its function, it is not surprising that deficiencies in the
lymphatic system are implicated in tumor growth [55].
Like in normal tissues, both vascular and lymphatic ves-
sels are present in malignant tissues, but some remarkable
differences from normal vessels have been observed. Un-
raveling alterations in lymphangiogenesis in tumors is of
major importance for understanding tumor spread. Both
vascular systems in a growing tumor share many common
features. Tumor blood vessels are highly disorganized, tor-
tous and dilated. They may display uneven diameter, ex-
cessive branching, shunts, and incomplete or absent
muscular coverage [56]. Consequently, tumor vessels are
leaky and blood flow is sluggish [57]. Lymphatic vessels in
pancreatic cancer have not been studied well, most likely
due to a lack of appropriate molecular markers, however,
lymphangiogenesis appears important in metastasis of
pancreatic cancer [58]. Morphological studies clearly indi-
cated alterations of lymphatic vessels in the periphery of
the tumors, where enlarged and well perfused lymphatic
vessels can be detected, whereas compressed and non-
functional vessels in the inside of the tumor can be seen
[59]. One explanation may be that neoplastic cells grown
in a confined space generate mechanical stress, compress-
ing the newly formed lymphatic channels inside the tu-
mor, while at the periphery, excess VEGF-C causes
lymphatics to enlarge. It is noteworthy that overexpres-
sion of the lymphangiogenic factor VEGF-C and expres-
sion of its receptor flt-4 has been reported recently for
pancreatic cancer where more than 2 fold higher levels for
VEGF-C can be detected in cancer tissue than in normal
pancreatic tissue [60]. The presence of VEGF-C in these
cells was associated with increased lymphatic vessels inva-
sion and lymph node metastasis, but not with decreased
patient survival. These findings suggest that VEGF-C and
its receptor are commonly overexpressed in human pan-
creatic cancers and may contribute to the lymphangiogen-
ic process and metastasis in this disease.
Conclusion
The most devastating aspect of cancer is the emergence of
metastases in organs distant from the primary tumor and
most deaths from cancer are related to metastases. Thus,
the understanding of the molecular mechanisms by which
metastases are generated is one of the most important is-
sues in cancer research. Recent advances in molecular bi-
ology have made it possible to identify genetic and
epigenetic determinants for tumor progression and metas-
tases. In fact, various genes including cell-cell adhesion
molecules (CAMs), members of the cadherin families and
integrins have been identified as modulators of metastatic
growth. Furthermore, metalloproteinases, the uPA/uPAR
system as well as the metastasis suppressor gene KAI1 ap-
pear to be crucial for the development of distant organ
metastasis. Last but not least the emerging role of angio-
genesis and lymphangiogenesis in invasion and metasta-
sis appeared to be critically important for tumor cell
dissemination. Based on this novel insights in mechanism
of tumor invasion and metastasis, novel therapies are cur-
rently in the final clinical stages to become available for
therapy of patients with pancreatic cancer.
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